title: [Dermatological implications of the PI3K pathway].
authors.affiliation: Département de dermatologie et unité Inserm U1058, université Montpellier I, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address: o-dereure@chu-montpellier.fr.
authors.forename: O
authors.initials: O
authors.lastname: Dereure
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002455:Cell Division / Q000502:physiology; D006222:Hamartoma / Q000201:enzymology; D006223:Hamartoma Syndrome, Multiple / Q000201:enzymology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000556:secondary; D058990:Molecular Targeted Therapy; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016715:Proteus Syndrome / Q000201:enzymology; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D012871:Skin Diseases / Q000145:classification / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D013577:Syndrome; D058570:TOR Serine-Threonine Kinases / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human; C546621:PIK3C2A protein, human; C494918:AKT1 protein, human; C494929:PTEN protein, human